Traders should monitor for upcoming developments regarding potential strategic transactions, such as a sale or partnership, especially given the recent engagement of a strategic advisor. The peer-reviewed validation may strengthen negotiation positioning.
Price Chart
Executive Summary
Catheter Precision announced that a clinical study on its LockeT device was accepted for publication in a peer-reviewed journal, validating its safety and efficacy for large-bore venous closure. This scientific endorsement supports the device's clinical value and aligns with the company's recent move to explore strategic options.
Key Facts
- Study on LockeT device accepted by the Journal of Interventional Cardiac Electrophysiology (JICE), a respected peer-reviewed journal.
- Study included 139 patients and demonstrated high procedural success, rapid hemostasis, early ambulation, and low complication rates.
- LockeT is a Class 1 device with FDA registration and CE Mark approval.
- Company recently engaged a strategic advisor to explore options for its electrophysiology product line.
Financial Impact
No immediate financial impact disclosed; potential long-term value creation through strategic transaction or commercial expansion.
Risk Factors
- No guarantee of near-term strategic deal or commercial uptake.
- Company has minimal market cap ($3M), suggesting high execution risk or limited resources.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3268387 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 18d ago | 8-K | $1.00 $0.8200 | ▲ +18.00% | ▲ +16.51% | $0.6500 (+35.00%) |
Oct 5, 2026 22d ago | Press Release | $1.62 $1.00 | ▼ −38.27% | ▼ −38.69% | $0.6500 (−59.88%) |
Oct 2, 2026 25d ago | 8-K | $1.62 $1.00 | ▼ −38.27% | ▼ −38.69% | $0.6500 (−59.88%) |
Oct 2, 2026 25d ago | Press Release | $1.62 $1.00 | ▼ −38.27% | ▼ −38.69% | $0.6500 (−59.88%) |
Sep 28, 2026 29d ago | Press Release | $0.1467 | awaiting T+5 | — | $0.6500 (+343.08%) |
Sep 25, 2026 4w ago | 8-K | $0.1467 | awaiting T+5 | — | $0.6500 (+343.08%) |
Aug 27, 2026 8w ago | Press Release | $0.2027 $0.1966 | ▼ −3.01% | ▼ −3.28% | $0.6500 (+220.67%) |
Aug 11, 2026 11w ago | Press Release | $0.2900 $0.2229 | ▼ −23.14% | ▼ −22.73% | $0.6500 (+124.14%) |
Aug 4, 2026 12w ago | Press Release | $0.2760 $0.2930 | ▲ +6.16% | ▲ +6.26% | $0.6500 (+135.51%) |
Jul 13, 2026 15w ago | EFFECT | $0.6504 $0.5020 | ▲ +22.82% | ▲ +21.87% | $0.6500 (+0.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers